View Older Stories View More Recent Stories

Dec 16, 2019 08:00AM  Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Dec 11, 2019 04:09PM Gilead Sciences' (GILD) Kite Submits BLA to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy
Dec 11, 2019 04:05PM Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy
Dec 11, 2019 08:31AM Kite (GILD), Kiniksa (KNSA) Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta and Mavrilimumab in R/R Large B-Cell Lymphoma
Dec 11, 2019 08:30AM Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
Dec 11, 2019 08:30AM Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
Dec 11, 2019 08:30AM Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
Dec 9, 2019 02:46PM Gilead Sciences' (GILD) Kite Presents Positive Results From Pivotal ZUMA-2 Trial in Relapsed or Refractory Mantle Cell Lymphoma
Dec 9, 2019 02:46PM Gilead Sciences' (GILD) Kite and CIBMTR Present Positive Findings From Real-World Use of Yescarta in Relapsed or Refractory Large B-Cell Lymphoma
Dec 9, 2019 02:45PM Kite Presents Positive Results From Pivotal ZUMA-2 Trial in Relapsed or Refractory Mantle Cell Lymphoma
Dec 9, 2019 02:45PM Kite and the CIBMTR® Present Positive Findings From Real-World Use of Yescarta® (Axicabtagene Ciloleucel) in Relapsed or Refractory Large B-Cell Lymphoma
Dec 7, 2019 02:00PM Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment
Nov 27, 2019 02:16PM National AIDS Memorial Receives $2.4 Million Donation From Gilead Sciences to Support the AIDS Memorial Quilt as It Moves Home to San Francisco
Nov 21, 2019 08:30AM Industry Veterans Appointed to Head the Global Technical Operations and Clinical Development Organizations at Kite
Nov 9, 2019 04:30PM NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE
Nov 9, 2019 04:30PM New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile
Nov 8, 2019 08:00AM Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019
Nov 8, 2019 08:00AM Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019
Nov 8, 2019 08:00AM Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy
Nov 6, 2019 09:03AM Gilead Sciences' (GILD) Kite to Present New Data From Industry-leading Cell Therapy Portfolio at ASH
Nov 6, 2019 09:00AM Kite to Present New Data From Industry-leading Cell Therapy Portfolio at ASH 2019
Nov 6, 2019 06:56AM Gilead Sciences (GILD) Reports Biktarvy Maintained High Efficacy w/no Cases of Treatment-Emergent Resistance Through 3-Yrs in Ph. 3 HIV Clinical Trials
Nov 6, 2019 06:45AM Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP®
Nov 6, 2019 06:45AM Gilead’s Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials
Oct 31, 2019 04:46PM Gilead Sciences (GILD), Galapagos (GLPG) to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting
Oct 31, 2019 04:01PM Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting
Oct 28, 2019 08:05AM Gilead Sciences (GILD), Glympse Bio Report Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development
Oct 28, 2019 08:00AM Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development
Oct 24, 2019 04:02PM Gilead Sciences Announces Fourth Quarter 2019 Dividend
Oct 15, 2019 08:30AM Gilead Sciences (GILD) Appoints Andrew Dickinson as CFO
Oct 15, 2019 08:30AM Gilead Sciences Appoints Andrew Dickinson as Chief Financial Officer
Oct 10, 2019 04:05PM Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 2019
Oct 8, 2019 06:21AM Gilead Sciences (GILD) Submits NDA for Filgotinib for Treatment of Adults With Rheumatoid Arthritis in Japan
Oct 8, 2019 02:00AM Gilead Sciences Submits New Drug Application for Filgotinib for the Treatment of Adults With Rheumatoid Arthritis in Japan
Oct 7, 2019 08:33AM Gilead Sciences (GILD) Names Merdad Parsey, MD, PhD Chief Medical Officer
Oct 7, 2019 08:30AM Gilead Sciences Appoints Merdad Parsey, MD, PhD as Chief Medical Officer
Oct 4, 2019 08:39AM Gilead Sciences (GILD) Presents New Data From the Company’s HIV Clinical Development Program and Latest Findings on the Impact of HIV PrEP at IDWeek
Oct 4, 2019 08:30AM Gilead Presents New Data From the Company’s HIV Clinical Development Program and Latest Findings on the Impact of HIV Pre-exposure Prophylaxis (PrEP) at IDWeek 2019
Oct 3, 2019 02:49PM Gilead Sciences (GILD) Announces U.S. FDA Approves Descovy for HIV Pre-Exposure Prophylaxis
Oct 3, 2019 02:49PM U.S. Food and Drug Administration Approves Descovy® for HIV Pre-Exposure Prophylaxis (PrEP)
Sep 9, 2019 07:30AM Gilead Sciences and the Elton John AIDS Foundation Launch RADIAN Initiative to Address HIV in Eastern Europe and Central Asia (EECA)
Sep 5, 2019 01:00AM Press Release Biocartis NV: Biocartis announces H1 2019 results
Aug 26, 2019 04:34PM Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10
Aug 23, 2019 04:01PM Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
Aug 15, 2019 04:02PM UPDATE: Gilead Sciences (GILD), Galapagos NV (GLPG) Report EMA Validates Marketing Application for Filgotinib for Treatment of Rheumatoid Arthritis
Aug 15, 2019 04:01PM European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
Aug 9, 2019 08:32AM Gilead Sciences (GILD) Announces China National Medical Products Administration Approves Biktarvy for Treatment of HIV-1 Infection
Aug 9, 2019 08:30AM China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Aug 8, 2019 07:42AM Agenus (AGEN) Reports FDA Acceptance of IND Filing for AGEN2373 Triggers $7.5M Milestone Payment from Gilead Sciences Inc. (GILD)
Aug 8, 2019 06:16AM Gilead Sciences (GILD) Statement on FDA Advisory Committee's Recommendation on Descovy for PrEP
View More Recent Stories View Older Stories